GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Naturewise Biotech & Medicals Corp (ROCO:4732) » Definitions » EV-to-EBIT

Naturewise Biotech & Medicals (ROCO:4732) EV-to-EBIT : 86.34 (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Naturewise Biotech & Medicals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Naturewise Biotech & Medicals's Enterprise Value is NT$861.3 Mil. Naturewise Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil. Therefore, Naturewise Biotech & Medicals's EV-to-EBIT for today is 86.34.

The historical rank and industry rank for Naturewise Biotech & Medicals's EV-to-EBIT or its related term are showing as below:

ROCO:4732' s EV-to-EBIT Range Over the Past 10 Years
Min: -48.52   Med: -4.31   Max: 89
Current: 86.34

During the past 13 years, the highest EV-to-EBIT of Naturewise Biotech & Medicals was 89.00. The lowest was -48.52. And the median was -4.31.

ROCO:4732's EV-to-EBIT is ranked worse than
91.29% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs ROCO:4732: 86.34

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Naturewise Biotech & Medicals's Enterprise Value for the quarter that ended in Dec. 2023 was NT$893.4 Mil. Naturewise Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil. Naturewise Biotech & Medicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1.12%.


Naturewise Biotech & Medicals EV-to-EBIT Historical Data

The historical data trend for Naturewise Biotech & Medicals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Naturewise Biotech & Medicals EV-to-EBIT Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.57 13.25 64.21 41.28 89.55

Naturewise Biotech & Medicals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.21 - 41.28 - 89.55

Competitive Comparison of Naturewise Biotech & Medicals's EV-to-EBIT

For the Biotechnology subindustry, Naturewise Biotech & Medicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Naturewise Biotech & Medicals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Naturewise Biotech & Medicals's EV-to-EBIT falls into.



Naturewise Biotech & Medicals EV-to-EBIT Calculation

Naturewise Biotech & Medicals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=861.320/9.976
=86.34

Naturewise Biotech & Medicals's current Enterprise Value is NT$861.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturewise Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Naturewise Biotech & Medicals  (ROCO:4732) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Naturewise Biotech & Medicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=9.976/893.3585
=1.12 %

Naturewise Biotech & Medicals's Enterprise Value for the quarter that ended in Dec. 2023 was NT$893.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Naturewise Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$10.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Naturewise Biotech & Medicals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Naturewise Biotech & Medicals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Naturewise Biotech & Medicals (ROCO:4732) Business Description

Traded in Other Exchanges
N/A
Address
No. 36, Bade Road, 6th Floor, Section 3, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.

Naturewise Biotech & Medicals (ROCO:4732) Headlines

No Headlines